Logo

Tempus xR Sequencing Assay

Jun 23, 2023

Tempus launched a new standalone RNA next-generation sequencing assay this week, dubbed Tempus xR, which covers clinically relevant fusions in more than 100 targeted genes, as well as altered splicing for MET Exon 14 and EGFRvIII. The test falls under the firm's existing standard of whole-genome and exome sequencing, but Tempus described xR as a new option for physicians that are specifically interested in RNA fusions or altered splicing, as well as providers, researchers, and biopharma companies seeking RNA sequencing analysis of existing samples. According to the company, the launch will divide its current operations, with its xT assay now providing DNA sequencing and xR offering RNA sequencing for clinical and research use.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.